- $707.65m
- $765.17m
- $202.09m
- 52
- 34
- 90
- 60
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -34.99% | ||
| Return on Equity | n/a | ||
| Operating Margin | -24.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 34.92 | 56.54 | 99.67 | 148.62 | 202.09 | 261.19 | 346.19 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Directors
- Vikram Malik CHM (58)
- David Moatazedi PRE (43)
- Lauren Silvernail CFO (63)
- Crystal Muilenburg CMO (41)
- Rui Avelar OTH (59)
- Simone Blank DRC (58)
- Peter Farrell IND (79)
- David Gill IND (66)
- Robert Hayman IND (62)
- Karah Parschauer IND (43)
- Brady Stewart IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 9th, 2012
- Public Since
- February 8th, 2018
- No. of Shareholders
- 36
- No. of Employees
- 273
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 61,374,621
- Address
- 520 Newport Center Dr Ste 1200, NEWPORT BEACH, 92660-7022
- Web
- https://www.evolus.com
- Phone
- +1 9492844555
- Contact
- Nareg Sagherian
- Auditors
- Ernst & Young LLP
Upcoming Events for EOLS
Evolus Inc Annual Shareholders Meeting
Q2 2024 Evolus Inc Earnings Release
Similar to EOLS
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
Alimera Sciences
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
FAQ
What is the Evolus share price?
As of Today at 19:08 UTC, shares in Evolus are trading at $11.53. This share price information is delayed by 15 minutes.
How has the Evolus share price performed this year?
Shares in Evolus last closed at $11.53 and the price had moved by +33.14% over the past 365 days. In terms of relative price strength the Evolus share price has outperformed the S&P500 Index by +10.79% over the past year.
What are the analyst and broker recommendations for Evolus?
The overall consensus recommendation for Evolus is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Evolus dividend yield?
Evolus does not currently pay a dividend.
Does Evolus pay a dividend?
Evolus does not currently pay a dividend.
When does Evolus next pay dividends?
Evolus does not currently pay a dividend.
How do I buy Evolus shares?
To buy shares in Evolus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Evolus?
As of the previous close price of $11.53, shares in Evolus had a market capitalisation of $707.65m.
Where are Evolus shares listed?
Here are the trading details for Evolus:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: EOLS
What kind of share is Evolus?
Based on an overall assessment of its quality, value and momentum Evolus is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Evolus share price forecast for 2024?
The analyst consensus target price for shares in Evolus is $22.29. That is 93.32% above the last closing price of $11.53.
Analysts covering Evolus currently have a consensus Earnings Per Share (EPS) forecast of -$0.35 for the next financial year.
What is the trend in the Evolus share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evolus. Over the past six months, its share price has outperformed the S&P500 Index by +25.33%.
As of the last closing price of $11.53, shares in Evolus were trading +9.96% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Evolus PE Ratio?
The Evolus PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $11.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Evolus?
Evolus' management team is headed by:
- Vikram Malik - CHM
- David Moatazedi - PRE
- Lauren Silvernail - CFO
- Crystal Muilenburg - CMO
- Rui Avelar - OTH
- Simone Blank - DRC
- Peter Farrell - IND
- David Gill - IND
- Robert Hayman - IND
- Karah Parschauer - IND
- Brady Stewart - IND